TREATMENT OF PATIENTS WITH SMALL CELL LUNG CANCER

在578名接受治疗的小细胞肺癌患者中，有62人在 国家癌症研究所(11%)在两年后没有癌症 启动小细胞肺癌的治疗。非小细胞肺癌的风险和 这些患者中的空气消化系统癌症患者从2%增加了6倍以上。 2-4年每名患者每年分别下降到12.6%和14.4%， 十多年过去了。一项保险的累积精算风险 16岁的第二原发非小细胞肺癌或空气消化系统癌分别为69%和72% 分别进行了分析。 B.来自九个不同机构的调查人员于 611例小细胞肺癌患者两年或两年内无瘤生存 再多几年。这些患者再次罹患肺癌的风险增加。 随着时间的推移，从确诊到超过24倍的十年或更长时间。胸部 辐射和持续吸烟都会增加大约2- 收牌。第二次癌症的累积精算风险在10岁时达到30%。 15年时为60%。这些患者都是 化学预防试验。 C.来自肺癌患者的28个肿瘤细胞株已经被 研究以确定增加持续时间(3、24和 120小时)暴露于紫杉醇。所需的中位数浓度 抑制14非小细胞肺癌细胞生长的50%(IC50) 线在三小时时为32微摩尔，而在三小时时为0.023微摩尔 暴露120小时。静脉滴注96小时的临床试验 紫杉醇联合顺铂治疗慢性粒细胞白血病 IV期非小细胞肺癌和广泛期小细胞肺癌 癌症。

A. Sixty-two of 578 patients treated for small cell lung cancer at the National Cancer Institute (11%) were cancer-free two years after initiation of therapy for small cell lung cancer. The risk of a NSCLC and aerodigestive cancer in these patients increased more than 6-fold, from 2% per patient per year during years 2-4 to 12.6% and 14.4% respectively, after more than 10 years had passed. The cumulative actuarial risk of a second primary NSCLC or aerodigestive cancer at 16 years is 69% and 72% respectively. B. Investigators from nine different institutions submitted their data on 611 patients with small cell lung cancer surviving cancer-free for two or more years. The risk of a second lung cancer in these patients increased with time to more than 24-fold ten years or more from diagnosis. Chest irradiation and continued smoking each increased the risk approximately 2- fold. The cumulative actuarial risk of a second cancer reaches 30% at ten years and 60% at 15 years. These patients are candidates for chemoprevention trials. C. Twenty-eight tumor cell lines from patients with lung cancer have been studied to determine the cytotoxicity of increasing durations (3, 24, and 120 hours) of exposure to paclitaxel. The median concentration required to inhibit 50% (IC5O) of the growth of 14 non-small cell lung cancer cell lines at three hours was > 32 micromolar compared to 0.023 micromolar when exposed for 120 hours. A clinical trial using 96 hour infusion of paclitaxel combined with cisplatin has been initiated for patients with stage IV non-small cell lung cancer and extensive stage small cell lung cancer.